vs

Side-by-side financial comparison of American Express (AXP) and Monte Rosa Therapeutics, Inc. (GLUE). Click either name above to swap in a different company.

American Express is the larger business by last-quarter revenue ($18.9M vs $12.8M, roughly 1.5× Monte Rosa Therapeutics, Inc.). American Express runs the higher net margin — 15.7% vs -212.1%, a 227.8% gap on every dollar of revenue. On growth, Monte Rosa Therapeutics, Inc. posted the faster year-over-year revenue change (38.5% vs 11.4%).

American Express Company, together with its subsidiaries, provides charge and credit payment card products, and travel-related services worldwide. The company operates through three segments: Global Consumer Services Group, Global Commercial Services, and Global Merchant and Network Services. Its products and services include payment and financing products; network services; accounts payable expense management products and services; and travel and lifestyle services. The company's products an...

Monte Rosa Therapeutics is a clinical-stage biotechnology company specializing in the discovery and development of targeted molecular glue degrader therapies. Its pipeline addresses unmet medical needs across oncology, rare genetic disorders and immunological diseases, with operations focused on advancing novel treatments for global patient populations.

AXP vs GLUE — Head-to-Head

Bigger by revenue
AXP
AXP
1.5× larger
AXP
$18.9M
$12.8M
GLUE
Growing faster (revenue YoY)
GLUE
GLUE
+27.1% gap
GLUE
38.5%
11.4%
AXP
Higher net margin
AXP
AXP
227.8% more per $
AXP
15.7%
-212.1%
GLUE

Income Statement — Q1 FY2026 vs Q3 FY2025

Metric
AXP
AXP
GLUE
GLUE
Revenue
$18.9M
$12.8M
Net Profit
$3.0M
$-27.1M
Gross Margin
Operating Margin
-258.3%
Net Margin
15.7%
-212.1%
Revenue YoY
11.4%
38.5%
Net Profit YoY
15.0%
-13.5%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXP
AXP
GLUE
GLUE
Q1 26
$18.9M
Q4 25
$10.9B
Q3 25
$10.4B
$12.8M
Q2 25
$10.3B
$23.2M
Q1 25
$9.6B
$84.9M
Q4 24
$10.0B
$60.6M
Q3 24
$9.7B
Q2 24
$9.8B
Net Profit
AXP
AXP
GLUE
GLUE
Q1 26
$3.0M
Q4 25
$2.5B
Q3 25
$2.9B
$-27.1M
Q2 25
$2.9B
$-12.3M
Q1 25
$2.6B
$46.9M
Q4 24
$2.2B
$13.4M
Q3 24
$2.5B
Q2 24
$3.0B
Operating Margin
AXP
AXP
GLUE
GLUE
Q1 26
Q4 25
28.2%
Q3 25
36.7%
-258.3%
Q2 25
34.4%
-67.1%
Q1 25
34.6%
51.9%
Q4 24
27.7%
21.4%
Q3 24
33.0%
Q2 24
38.6%
Net Margin
AXP
AXP
GLUE
GLUE
Q1 26
15.7%
Q4 25
22.5%
Q3 25
27.9%
-212.1%
Q2 25
28.0%
-53.0%
Q1 25
26.8%
55.2%
Q4 24
21.8%
22.2%
Q3 24
25.8%
Q2 24
30.7%
EPS (diluted)
AXP
AXP
GLUE
GLUE
Q1 26
Q4 25
$3.52
Q3 25
$4.14
Q2 25
$4.08
Q1 25
$3.64
Q4 24
$3.04
Q3 24
$3.49
Q2 24
$4.15

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXP
AXP
GLUE
GLUE
Cash + ST InvestmentsLiquidity on hand
$208.3M
Total DebtLower is stronger
$60.4M
Stockholders' EquityBook value
$34.0M
$245.8M
Total Assets
$308.9M
$459.8M
Debt / EquityLower = less leverage
1.78×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXP
AXP
GLUE
GLUE
Q1 26
Q4 25
$742.0M
Q3 25
$1.3B
$208.3M
Q2 25
$197.0M
$69.4M
Q1 25
$261.0M
$78.5M
Q4 24
$221.0M
$224.3M
Q3 24
$120.0M
Q2 24
$188.0M
Total Debt
AXP
AXP
GLUE
GLUE
Q1 26
$60.4M
Q4 25
$56.4B
Q3 25
$57.8B
Q2 25
$58.2B
Q1 25
$51.2B
Q4 24
$49.7B
Q3 24
$53.5B
Q2 24
$51.5B
Stockholders' Equity
AXP
AXP
GLUE
GLUE
Q1 26
$34.0M
Q4 25
$33.5B
Q3 25
$32.4B
$245.8M
Q2 25
$32.3B
$268.1M
Q1 25
$31.2B
$275.2M
Q4 24
$30.3B
$222.9M
Q3 24
$29.7B
Q2 24
$29.5B
Total Assets
AXP
AXP
GLUE
GLUE
Q1 26
$308.9M
Q4 25
$300.1B
Q3 25
$297.6B
$459.8M
Q2 25
$295.6B
$359.6M
Q1 25
$282.2B
$393.2M
Q4 24
$271.5B
$438.7M
Q3 24
$271.0B
Q2 24
$272.2B
Debt / Equity
AXP
AXP
GLUE
GLUE
Q1 26
1.78×
Q4 25
1.68×
Q3 25
1.78×
Q2 25
1.80×
Q1 25
1.64×
Q4 24
1.64×
Q3 24
1.80×
Q2 24
1.74×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXP
AXP
GLUE
GLUE
Operating Cash FlowLast quarter
$100.4M
Free Cash FlowOCF − Capex
$99.8M
FCF MarginFCF / Revenue
781.5%
Capex IntensityCapex / Revenue
5.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$145.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXP
AXP
GLUE
GLUE
Q1 26
Q4 25
$3.1B
Q3 25
$6.2B
$100.4M
Q2 25
$4.4B
$-34.7M
Q1 25
$4.8B
$-45.5M
Q4 24
$5.8B
$128.9M
Q3 24
$-1.8B
Q2 24
$4.5B
Free Cash Flow
AXP
AXP
GLUE
GLUE
Q1 26
Q4 25
$2.3B
Q3 25
$5.6B
$99.8M
Q2 25
$3.7B
$-36.4M
Q1 25
$4.3B
$-47.1M
Q4 24
$5.3B
$128.7M
Q3 24
$-2.3B
Q2 24
$4.0B
FCF Margin
AXP
AXP
GLUE
GLUE
Q1 26
Q4 25
21.4%
Q3 25
53.6%
781.5%
Q2 25
36.3%
-157.0%
Q1 25
45.0%
-55.4%
Q4 24
53.1%
212.3%
Q3 24
-23.3%
Q2 24
40.4%
Capex Intensity
AXP
AXP
GLUE
GLUE
Q1 26
Q4 25
6.6%
Q3 25
6.3%
5.1%
Q2 25
6.0%
7.3%
Q1 25
4.5%
1.9%
Q4 24
5.0%
0.3%
Q3 24
4.7%
Q2 24
5.8%
Cash Conversion
AXP
AXP
GLUE
GLUE
Q1 26
Q4 25
1.25×
Q3 25
2.15×
Q2 25
1.51×
Q1 25
1.84×
-0.97×
Q4 24
2.66×
9.59×
Q3 24
-0.72×
Q2 24
1.50×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AXP
AXP

Discount revenue$9.5M50%
Other$8.9M47%
Deposits with banks and other$512.0K3%

GLUE
GLUE

Segment breakdown not available.

Related Comparisons